Skip to main content
DSNKY logo

Daiichi Sankyo Company, Limited (DSNKY) Stock Price & Analysis

Daiichi Sankyo Company, Limited (DSNKY) — price $16.95 (-0.94%), as of the Nov 20, 2026 trading session; market cap $30.9B.

Educational signal · not a buy or sell recommendation · How to read this

$16.95 −$0.16 (-0.94%) Market Cap $30.9B

Daiichi Sankyo Company, Limited · DSNKY · Healthcare · Drug Manufacturers - General

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal…

Price as of Nov 20, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • BIIB · Biogen Inc. · 37 /100
  • GSK · GSK plc · 77 /100
  • SNY · Sanofi · 87 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$16.95
Change on the day-0.94%
52-week range$14.98–$24.77
Market capitalisation$30.9B—
Price / earnings (trailing)18.00
Shares traded on the day9.6K
Beta (volatility vs the S&P 500)0.14

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $15, high $27, latest $17. $27 $15 high $27 Oct 17, 2025 Nov 20, 2026 · $17 $27Oct 17, 2025$24Oct 31, 2025$23Nov 14, 2025$25Nov 28, 2025$21Dec 12, 2025$22Dec 26, 2025$23Jan 9, 2026$20Jan 23, 2026$18Feb 6, 2026$19Feb 20, 2026$18Mar 6, 2026$18Mar 20, 2026$18Apr 2, 2026$19Apr 17, 2026$17May 1, 2026$16May 15, 2026$17May 29, 2026$16Jun 12, 2026$16Jun 26, 2026$17Jul 10, 2026$17Jul 24, 2026$18Aug 7, 2026$18Aug 21, 2026$18Sep 4, 2026$19Sep 18, 2026$17Oct 2, 2026$17Oct 16, 2026$17Oct 30, 2026$18Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Daiichi Sankyo Company (DSNKY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Debt/Equity Moderate
ROE Moderate
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Daiichi Sankyo Company (DSNKY), and what does it report?

Short answer

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal… Healthcare / Drug Manufacturers General Headquarters: Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP. It employs 20,171 people and is led by Hiroyuki Okuzawa. The market values it at $30.9B.

3 · Financial strengths and risks

What are the financial strengths and risks for Daiichi Sankyo Company (DSNKY)?

Short answer

The distress and quality screens read Altman Z 2.95 · Piotroski F 6. Trailing ratios: ROE 17.6% · ROA 4.6% · current ratio 2.81.

5 · Score methodology

How is Daiichi Sankyo Company scored?

Research dated 2026-09-12.

Daiichi Sankyo differs from oncology-focused biotechnology companies because its economics include a broad marketed portfolio, vaccines, consumer health products and pharmaceutical manufacturing activities. Enhertu gives oncology strategic importance, but the company is not a product-pure cancer developer.

Relative to diversified drug manufacturers, its notable feature is the combination of an antibody-drug conjugate franchise with development of a Guardant companion diagnostic for Enhertu in advanced metastatic lung cancer. That pairing links medicine commercialization with patient selection, while the consolidated accounts still blend newer oncology assets with mature therapies and consumer products.

The shares trade through an over-the-counter quotation, while the operating company is headquartered in Tokyo and distributes medicines globally. That listing route differs from the business itself and should not be read as evidence of a narrowly domestic operation.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Ipsen S.A. (IPSEY) Named competitor$45.10 Nov 20, 2026$14.9B— Model unavailable
UCB S.A. (UCBJF) Named competitor$318.32 Nov 20, 2026$60.7B— Model unavailable
HOYA Corporation (HOCPF) Named competitor$143.12 Nov 20, 2026$47.5B— Model unavailable
Takeda Pharmaceutical Company Limited (TKPHF) Named competitor$43.05 Nov 20, 2026$68.8B— Model unavailable
WuXi AppTec Co., Ltd. (WUXIF) Named competitor$23.77 Nov 20, 2026$72.2B— Model unavailable
Biogen Inc. (BIIB) Same industry, near in market value$247.13 Nov 19, 2026$36.5B— 5-pillar · not comparable
GSK plc (GSK) Same industry, near in market value$47.76 Nov 20, 2026$95.7B— 5-pillar · not comparable
Sanofi (SNY) Same industry, near in market value$46.06 Nov 19, 2026$111B— 5-pillar · not comparable
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$58.80 Nov 20, 2026$120B— 5-pillar · not comparable
Pfizer Inc. (PFE) Same industry, near in market value$27.54 Nov 19, 2026$157B— 5-pillar · not comparable
Grifols, S.A. (GRFS) Same industry, near in market value$8.15 Nov 20, 2026$5.55B— 5-pillar · not comparable
Gilead Sciences, Inc. (GILD) Same industry, near in market value$166.53 Nov 19, 2026$207B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DSNKY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DSNKY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Daiichi Sankyo Company (DSNKY)?

Read these with our analysis →

Daiichi Sankyo Company Healthcare Stock: Key Questions Answered

The last question is answered from this page's own dated data, not from the research.

Does Enhertu make Daiichi Sankyo a pure oncology company?

Enhertu is an important antibody-drug conjugate, but Daiichi Sankyo also sells medicines across cardiovascular, metabolic, neurological, pain, bone and infectious diseases, as well as vaccines and consumer health products.

How does the Guardant companion diagnostic fit with Enhertu?

Daiichi Sankyo is collaborating with Guardant Health on a companion diagnostic specifically for Enhertu use in advanced metastatic lung cancer. The development connects treatment commercialization with identification of suitable patients.

What is the DSNKY stock price today?

The last price recorded for Daiichi Sankyo Company, Limited (DSNKY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 12 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • 5. How is Daiichi Sankyo Company scored?: Business description; Sector / industry (provider taxonomy); Ticker / exchange; Headquarters
  • FAQ: Does Enhertu make Daiichi Sankyo a pure oncology company?: Business description
  • FAQ: How does the Guardant companion diagnostic fit with Enhertu?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.